GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (FRA:VTFN) » Definitions » Cyclically Adjusted PS Ratio

Vitrolife AB (FRA:VTFN) Cyclically Adjusted PS Ratio : 11.46 (As of Jun. 24, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Vitrolife AB Cyclically Adjusted PS Ratio?

As of today (2024-06-24), Vitrolife AB's current share price is €15.36. Vitrolife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.34. Vitrolife AB's Cyclically Adjusted PS Ratio for today is 11.46.

The historical rank and industry rank for Vitrolife AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:VTFN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.74   Med: 25.18   Max: 62.6
Current: 11.12

During the past years, Vitrolife AB's highest Cyclically Adjusted PS Ratio was 62.60. The lowest was 8.74. And the median was 25.18.

FRA:VTFN's Cyclically Adjusted PS Ratio is ranked worse than
89.12% of 478 companies
in the Medical Devices & Instruments industry
Industry Median: 2.075 vs FRA:VTFN: 11.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vitrolife AB's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.549. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €1.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vitrolife AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vitrolife AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB Cyclically Adjusted PS Ratio Chart

Vitrolife AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.65 27.00 59.40 14.74 12.79

Vitrolife AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.31 15.00 10.12 12.79 12.78

Competitive Comparison of Vitrolife AB's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Vitrolife AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Cyclically Adjusted PS Ratio falls into.



Vitrolife AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vitrolife AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=15.36/1.34
=11.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vitrolife AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.549/132.2054*132.2054
=0.549

Current CPI (Mar. 2024) = 132.2054.

Vitrolife AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.144 100.432 0.190
201409 0.137 100.161 0.181
201412 0.134 100.225 0.177
201503 0.162 99.950 0.214
201506 0.183 99.995 0.242
201509 0.173 100.228 0.228
201512 0.198 100.276 0.261
201603 0.185 100.751 0.243
201606 0.205 101.019 0.268
201609 0.202 101.138 0.264
201612 0.238 102.022 0.308
201703 0.236 102.022 0.306
201706 0.270 102.752 0.347
201709 0.237 103.279 0.303
201712 0.251 103.793 0.320
201803 0.239 103.962 0.304
201806 0.254 104.875 0.320
201809 0.251 105.679 0.314
201812 0.287 105.912 0.358
201903 0.274 105.886 0.342
201906 0.330 106.742 0.409
201909 0.326 107.214 0.402
201912 0.360 107.766 0.442
202003 0.283 106.563 0.351
202006 0.184 107.498 0.226
202009 0.283 107.635 0.348
202012 0.346 108.296 0.422
202103 0.343 108.360 0.418
202106 0.348 108.928 0.422
202109 0.340 110.338 0.407
202112 0.403 112.486 0.474
202203 0.527 114.825 0.607
202206 0.577 118.384 0.644
202209 0.546 122.296 0.590
202212 0.574 126.365 0.601
202303 0.562 127.042 0.585
202306 0.573 129.407 0.585
202309 0.529 130.224 0.537
202312 0.598 131.912 0.599
202403 0.549 132.205 0.549

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vitrolife AB  (FRA:VTFN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vitrolife AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB (FRA:VTFN) Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive advanced support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction.

Vitrolife AB (FRA:VTFN) Headlines

No Headlines